Eom Bang Wool, Kim Young-Il, Yoon Hong Man, Cho Soo-Jeong, Lee Jong Yeul, Kim Chan Gyoo, Kim Soo Jin, Rho Ji Yoon, Kim Seok Ki, Kook Myeong-Cherl, Kim Young-Woo, Ryu Keun Won
Center for Gastric Cancer.
Chin J Cancer Res. 2017 Apr;29(2):93-99. doi: 10.21147/j.issn.1000-9604.2017.02.01.
Although a number of feasibility studies for sentinel node (SN) concepts in gastric cancer have been conducted since 2000, there remains a debate regarding detailed detection techniques and oncological safety. Two important multicenter phase II clinical trials were performed in Japan that used different methods and reached different conclusions; one confirmed acceptable results with a false-negative rate of 7%, and the other showed an unacceptably high false-negative rate of 46.4%. The Sentinel Node Oriented Tailored Approach (SENORITA) trial is a multicenter randomized controlled phase III trial being performed in Korea. Patient enrollment is now complete and the long-term results are currently awaited. Recently, an image-guided SN mapping technique using infrared ray/fluorescence was introduced. This method might be a promising technology because it allows the clear visualization of SNs. With regard to the primary tumor, the non-exposed endoscopic wall-inversion surgery technique and non-exposure endolaparoscopic full-thickness resection with simple suturing technique have been reported. These methods prevent abdominal infection and tumor seeding and can be good alternatives to conventional laparoscopic gastric wedge resection. For indications, SN navigation surgery can be extended to patients who underwent non-curative endoscopic resection. Although a few studies have been performed on these patients, sentinel concepts may be beneficial to patients as they omit the need for additional gastrectomy. SN navigation surgery can lead to actual organ-preserving surgery and plays a key role in improving the quality of life of patients with early gastric cancer in the future.
自2000年以来,虽然已经开展了多项关于胃癌前哨淋巴结(SN)概念的可行性研究,但在详细检测技术和肿瘤学安全性方面仍存在争议。日本进行了两项重要的多中心II期临床试验,采用了不同方法并得出了不同结论;一项试验确认结果可接受,假阴性率为7%,另一项试验则显示出高达46.4%的不可接受的假阴性率。前哨淋巴结导向的个体化治疗方法(SENORITA)试验是在韩国进行的一项多中心随机对照III期试验。目前患者入组已完成,正在等待长期结果。最近,引入了一种使用红外线/荧光的图像引导SN定位技术。这种方法可能是一项有前景的技术,因为它能使SN清晰可视化。关于原发性肿瘤,已报道了非暴露内镜壁翻转手术技术和非暴露腹腔镜全层切除并简单缝合技术。这些方法可预防腹腔感染和肿瘤播散,可能是传统腹腔镜胃楔形切除术的良好替代方法。对于适应证,SN导航手术可扩展至接受非根治性内镜切除的患者。虽然对这些患者进行的研究较少,但前哨淋巴结概念可能对患者有益,因为可避免额外的胃切除术。SN导航手术可实现实际的器官保留手术,并在未来改善早期胃癌患者的生活质量方面发挥关键作用。